A revolutionary device developed by a team of Cambridge scientists is transforming the diagnosis of HIV in sub-Saharan Africa. The machine — known as SAMBA, or simple amplification-based assay — can help determine whether a person is infected with the virus within two hours of them giving a tiny blood sample. Virus carriers can then be offered immediate treatment and advice.
More than 20 million people in sub-Saharan Africa are thought to be carrying HIV, the virus that causes AIDS. The chaotic conditions in some parts of the region — with transport, health services and electricity supply often poor or nonexistent — have made it extraordinarily difficult for doctors to keep track of infected people.
The new analyser — the size of a small coffee machine — which was developed by a team led by Helen Lee, a Cambridge University professor of blood scientist, needs no laboratory or trained staff. It can be carried on a motorcycle — often the only method of transport in remote regions — and its reagents can withstand high temperatures and humidity.
“Basically, they will still work even if the heat goes above 50oC,” Lee said.
In recognition of her team’s achievement in developing SAMBA, Lee has been named a finalist in this year’s European inventor awards. Winners are to be announced in Lisbon this week.
“The crucial point about our device is that it provides you with a simple signal,” Lee told the Observer. “If two lights are produced, that shows a person has been infected with HIV. If only one light shines, they are not infected. We can show it to a patient and explain to them exactly what the lights mean and what is going on. That is a very powerful way to convince someone of their condition.”
Working in close collaboration with charity Medecins Sans Frontieres, Lee and her colleagues have tested SAMBA on 40,000 men and women in Malawi and Uganda since the first prototype was developed in 2011 and found it works extremely efficiently. Each test costs about £12 (US$17.6) to administer.
“Now we are going to expand testing for HIV to pregnant women, mothers and newborn children, starting in Kenya,” Lee said. “That has all sorts of potential. For example, if we find a woman is infected, but not her newborn child, we can give advice her about how to prevent the baby picking up the virus during his or her infancy.”
The ability to make quick diagnoses is considered to be of crucial importance in controlling HIV in Africa. Until now, people have had to travel to health centers to provide a blood sample and then return weeks later for the results of their test. Up to 70 percent of patients will fail to return and are designated “lost to follow-up.” Lee’s tests should help to cut that number dramatically.
“We are taking the test to the people rather than the other way around,” she said.
This point was backed by Benoit Battistelli, president of the European Patent Office, which is running the inventor awards.
“The test brings reliable diagnostics of HIV infection to areas where they are needed most and will also allow monitoring of the efficiency of medical treatments without laboratory infrastructure,” Battistelli said.
Apart from giving reliable diagnoses of HIV infection, Lee’s device can tell doctors the viral load — the amount of live virus material — that is flowing through a patient’s bloodstream. This a critical parameter for gauging drug dosages and was previously available only in advanced laboratory settings.
SAMBA works by drawing a blood sample from a patient and then feeding it into a disposable cartridge that contains chemicals, including a particular genetic sequence found only in HIV. These chemicals do not require refrigeration and amplify the viral DNA to generate a color change that appears on the cartridge. Two red lines on the side mean that person is positive for HIV. One line means they are uninfected. No line means that the test has not worked and needs to be retaken.
“So many devices for dealing with conditions like HIV are created in the developed world,” Lee said. “Then scientists try to adapt them to suit the developing world. That always causes problems. So we have designed our system to suit developing countries from the start.”
James Watson — the Nobel laureate co-credited with the pivotal discovery of DNA’s double-helix structure, but whose career was later tainted by his repeated racist remarks — has died, his former lab said on Friday. He was 97. The eminent biologist died on Thursday in hospice care on Long Island in New York, announced the Cold Spring Harbor Laboratory, where he was based for much of his career. Watson became among the 20th century’s most storied scientists for his 1953 breakthrough discovery of the double helix with researcher partner Francis Crick. Along with Crick and Maurice Wilkins, he shared the
OUTRAGE: The former strongman was accused of corruption and responsibility for the killings of hundreds of thousands of political opponents during his time in office Indonesia yesterday awarded the title of national hero to late president Suharto, provoking outrage from rights groups who said the move was an attempt to whitewash decades of human rights abuses and corruption that took place during his 32 years in power. Suharto was a US ally during the Cold War who presided over decades of authoritarian rule, during which up to 1 million political opponents were killed, until he was toppled by protests in 1998. He was one of 10 people recognized by Indonesian President Prabowo Subianto in a televised ceremony held at the presidential palace in Jakarta to mark National
US President Donald Trump handed Hungarian Prime Minister Viktor Orban a one-year exemption from sanctions for buying Russian oil and gas after the close right-wing allies held a chummy White House meeting on Friday. Trump slapped sanctions on Moscow’s two largest oil companies last month after losing patience with Russian President Vladimir Putin over his refusal to end the nearly four-year-old invasion of Ukraine. However, while Trump has pushed other European countries to stop buying oil that he says funds Moscow’s war machine, Orban used his first trip to the White House since Trump’s return to power to push for
LANDMARK: After first meeting Trump in Riyadh in May, al-Sharaa’s visit to the White House today would be the first by a Syrian leader since the country’s independence Syrian President Ahmed al-Sharaa arrived in the US on Saturday for a landmark official visit, his country’s state news agency SANA reported, a day after Washington removed him from a terrorism blacklist. Sharaa, whose rebel forces ousted long-time former Syrian president Bashar al-Assad late last year, is due to meet US President Donald Trump at the White House today. It is the first such visit by a Syrian president since the country’s independence in 1946, according to analysts. The interim leader met Trump for the first time in Riyadh during the US president’s regional tour in May. US envoy to Syria Tom Barrack earlier